64x Bio

64x Bio last raised a $55M Series A in 2022 (roughly $60M total), and no larger round has surfaced since — a long stretch for a capital-intensive cell-engineering company in a gene-therapy funding winter that has hollowed out its own customer base. That is the core tension: 64x sells into a market whose demand is contracting, as high-profile AAV programs stall, get shelved, or lose their sponsors to consolidation, and where the addressable buyers are a small, concentrated set of CDMOs and large-pharma manufacturing groups with the leverage to demand pilots before paying. "Strategic collaborations to evaluate" the AAV Apex Suite are exactly that — evaluations, not committed revenue — and the sales cycle from a producer-line trial to qualified GMP production is measured in years, with switching costs that cut both ways: incumbents entrenched in existing HEK293 workflows are hard to dislodge. The competitive field is not empty either; large tools and cell-line vendors (Thermo, Sartorius-adjacent suppliers, and vector-focused CDMOs building proprietary lines in-house) can bundle yield improvements into existing relationships. And stable cell lines — the real prize over transient transfection — remain "in development" per the company's own framing, meaning the highest-value product isn't shipping yet. A tools company this thinly capitalized, selling into a depressed end market, needs a fresh raise on terms a cautious 2026 biotech market may not offer.